269 related articles for article (PubMed ID: 33219572)
1. From dermatological conditions to COVID-19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy.
Criado PR; Miot HA; Pincelli TPH; Fabro AT
Dermatol Ther; 2021 Jan; 34(1):e14565. PubMed ID: 33219572
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulation for COVID-19 Patients: A Bird's-Eye View.
Kreidieh F; Temraz S
Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937
[TBL] [Abstract][Full Text] [Related]
3. Medium-pressure hyperbaric oxygen therapy for livedoid vasculopathy.
Herrera-Sánchez A; Madriagal-Alvarado MJ; Moncayo G; Verdini F
Medicina (B Aires); 2022; 82(4):613-616. PubMed ID: 35904919
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 lung disease in a patient with pulmonary sarcoidosis - case report.
Opoka LM; Wyrostkiewicz D; Winek J; Błasińska K; Miłkowska-Dymanowska J; Szturmowicz M
Adv Respir Med; 2020; 88(6):620-625. PubMed ID: 33393657
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action.
Pavoni V; Gianesello L; Pazzi M; Stera C; Meconi T; Frigieri FC
Thromb Res; 2020 Dec; 196():313-317. PubMed ID: 32977129
[TBL] [Abstract][Full Text] [Related]
6. Physiologic and biochemical rationale for treating COVID-19 patients with hyperbaric oxygen.
Feldmeier JJ; Kirby JP; Buckey JC; Denham DW; Evangelista JS; Gelly HB; Harlan NP; Mirza ZK; Ray KL; Robins M; Savaser DJ; Wainwright S; Bird N; Huang ET; Moon RE; Thom SR; Weaver LK
Undersea Hyperb Med; 2021; 48(1):1-12. PubMed ID: 33648028
[TBL] [Abstract][Full Text] [Related]
7. Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study.
Arnold F; Westermann L; Rieg S; Neumann-Haefelin E; Biever PM; Walz G; Kalbhenn J; Tanriver Y
BMC Nephrol; 2020 Nov; 21(1):486. PubMed ID: 33198670
[TBL] [Abstract][Full Text] [Related]
8. Livedoid vasculopathy successfully treated with hyperbaric oxygen.
Banham ND
Diving Hyperb Med; 2013 Mar; 43(1):35-6. PubMed ID: 23508660
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
10. Hyperbaric oxygen treatment for long coronavirus disease-19: a case report.
Bhaiyat AM; Sasson E; Wang Z; Khairy S; Ginzarly M; Qureshi U; Fikree M; Efrati S
J Med Case Rep; 2022 Feb; 16(1):80. PubMed ID: 35168680
[TBL] [Abstract][Full Text] [Related]
11. The outcomes of COVID-19 measures in a hyperbaric oxygen therapy centre during the pandemic.
Ozgok-Kangal K; Zaman T; Koc B
Int Marit Health; 2021; 72(3):228-236. PubMed ID: 34604994
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 coagulopathy - what should we treat?
Chowdary P
Exp Physiol; 2022 Jul; 107(7):749-758. PubMed ID: 35733235
[TBL] [Abstract][Full Text] [Related]
13. Dermatological aspects of SARS-CoV-2 infection: mechanisms and manifestations.
Garduño-Soto M; Choreño-Parra JA; Cazarin-Barrientos J
Arch Dermatol Res; 2021 Oct; 313(8):611-622. PubMed ID: 33159236
[TBL] [Abstract][Full Text] [Related]
14. Intractable livedoid vasculopathy successfully treated with hyperbaric oxygen.
Yang CH; Ho HC; Chan YS; Liou LB; Hong HS; Yang LC
Br J Dermatol; 2003 Sep; 149(3):647-52. PubMed ID: 14511004
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation.
Salabei JK; Fishman TJ; Asnake ZT; Ali A; Iyer UG
Heart Lung; 2021; 50(2):357-360. PubMed ID: 33524866
[TBL] [Abstract][Full Text] [Related]
16. Livedoid vasculopathy: fast involution after anticoagulant and hyperbaric oxygen therapy.
Bollmann PW; Shimada AK; Michalany NS; Manhani AR; Giglio AD
Einstein (Sao Paulo); 2011 Jun; 9(2):212-5. PubMed ID: 26760818
[TBL] [Abstract][Full Text] [Related]
17. UHMS Position Statement: Hyperbaric Oxygen (HBO2) for COVID-19 Patients.
Undersea Hyperb Med; 2020; 47(2):297-298. PubMed ID: 32574446
[TBL] [Abstract][Full Text] [Related]
18. Livedoid Vasculopathy with Hyperhomocysteinemia Responding to Hyperbaric Oxygen Therapy.
Ray R; Sharma A; Vasudevan B; Sridhar J; Deo R; Mohanty CS
Indian J Dermatol; 2015; 60(5):524. PubMed ID: 26538741
[TBL] [Abstract][Full Text] [Related]
19. Treatment for Livedoid Vasculopathy: A Systematic Review.
Micieli R; Alavi A
JAMA Dermatol; 2018 Feb; 154(2):193-202. PubMed ID: 29141075
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients.
Volteas P; Drakos P; Alkadaa LN; Cleri NA; Asencio AA; Oganov A; Giannopoulos S; Saadon JR; Mikell CB; Rubano JA; Labropoulos N; Tassiopoulos AK; Mofakham S; Bannazadeh M
J Vasc Surg Venous Lymphat Disord; 2022 Sep; 10(5):1128-1136. PubMed ID: 35716998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
